CanaQuest Signs MENTANINE® and MENTABINOL® Production and Distribution Agreement with Purcann Pharma and Silicycle Inc.

Published: February 3, 2021

CanaQuest Signs MENTANINE® and MENTABINOL® Production and Distribution Agreement with Purcann Pharma and Silicycle Inc.

CanaQuest MedicalCorp.a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced a new production and distribution agreement with PurCann Pharma and SiliCycle Inc. PurCann, a subsidiary of SiliCycle, is recognized for its unique expertise in the Extraction-Purification and commercialization of cannabinoids.

This agreement facilitates CanaQuest’s planned production, distribution and global export of Mentanine® and Mentabinol® formulations, through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License from Health Canada under the Cannabis Act. Initial sales are anticipated within 16 weeks after funding.

Hugo St-Laurent, PurCann, President, stated, “Mentanine® and Mentabinol® perfectly align with our strategic objectives. CanaQuest can benefit from SiliCycle and PurCann’s robust Canadian distribution channels and also leverage our organization’s international pharmaceutical health product marketing expertise across more than 100 countries.“

Paul Ramsay, CanaQuest Co-Founder & President, added, “We are extremely pleased to have PurCann Pharma, a Health Canada Licenced Processor and its parent company SiliCycle as new partners for our medicinal formulated products rollout, reflecting their exceptionally high pharma quality standards, expertise and processing capabilities.“

CanaQuest – Commercial Ready Master Formulations:
Mentanine®, Omega-3 + CBD based formulation, non-psychotic – increases the efficacy of CBD at a specific nuclear receptor in the brain, for the treatment of mental ailments. The formulation interacts with the Central Nervous System “CNS” that controls anxiety, depression, schizophrenia, Post Traumatic Stress Disorder “PTSD”, and addiction. Additionally, the improved efficacy (sublingually delivered) requires substantially smaller doses of CBD, thus, eliminating or minimizing existing liver toxicity caused by high oral consumption of CBD (as noted in a recent FDA comment).

Mentabinol®, THC based formulation & L-theanine – a safer alternative, for people who are taking THC for mental ailments, chronic pain, chemotherapy side-effects or for reducing anxiety or depression. The formulation could also be a viable treatment for opioid addiction.

Both formulations, are scientifically developed and proven by pre-clinical trials at Western University by a scientific team lead by Dr. Steven Laviolette. CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade).

For more information on CanaQuest, visit http://www.canaquest.com

SiliCycle Group is a world leader in the development, manufacturing, and marketing of specialty products for the pharmaceutical and health sciences industry. For more information on PurCann, visit https://www.purcannpharma.com/

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article